News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
163 Results
Type
Article (1)
Company Profile (1)
Press Release (161)
Section
Business (38)
Deals (4)
Drug Development (14)
FDA (2)
News (54)
Tag
2027 Genetown Standard (1)
Accelerated approval (1)
Alliances (1)
Approvals (2)
Biotechnology (1)
Clinical research (14)
Compensation (5)
C-suite (1)
Data (8)
Duchenne muscular dystrophy (13)
Earnings (22)
Events (52)
Executive appointments (1)
FDA (6)
Healthcare (8)
IPO (4)
People (26)
Phase 1 (11)
Phase 2 (12)
Phase 3 (3)
Pipeline (8)
Preclinical (10)
Rare diseases (1)
Regulatory (6)
Startups (1)
Date
Last 30 days (4)
Last 365 days (34)
2026 (19)
2025 (33)
2024 (31)
2023 (18)
2022 (19)
2021 (21)
2020 (15)
2019 (7)
Location
Asia (2)
Japan (2)
Massachusetts (69)
United States (69)
163 Results for "Dyne_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 18, 2026
June 19, 2026
·
2 min read
Press Releases
Dyne Therapeutics Appoints Barry Greene to Board of Directors
June 23, 2026
·
6 min read
Press Releases
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
June 17, 2026
·
6 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 20, 2026
May 21, 2026
·
2 min read
Press Releases
Dyne Therapeutics to Participate in Upcoming Investor Conferences - May 13, 2026
May 13, 2026
·
1 min read
Press Releases
Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
June 3, 2026
·
7 min read
Press Releases
Dyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
May 26, 2026
·
7 min read
Press Releases
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 23, 2026
April 24, 2026
·
2 min read
Press Releases
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
May 20, 2026
·
10 min read
Press Releases
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
April 28, 2026
·
7 min read
1 of 17
Next
